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• The pivotal Issue of transplant rejection diagnosis and management Is design, conduct, and analysis of clinical 
trials. The historical experience with clinical trials of major immunosuppressive drugs (cyclosporine and especially 
tacrollmus) Is examined in this article. Cyclosporlne was a turning point In transplantation, providing an extraordi-
nary Improvement over previous therapies. Additionally, early Investigational experience with tacrolimus was 
shown to be Important In rescue from cyclosporlne failure. experience with tacrollmus In liver reCipients for primary 
therapy led to understanding that the side effect profile was similar to cyclosporlne and that the Important side 
effects of tacrollmus (toxicity and diabetes) could be lessened by altering the drug dose. Early doSing regimens 
were determined by attempts to balance the toxicities (representing a dose ceiling) against rejection (for minimum 
dosing). Drug levels became understandable and trough levels could be used to guide therapy. However, when the 
multicenter liver trial was Implemented, high starting doses were Included In the protocol deSign, Ignoring 
Information obtained with drug level monitoring. Disregard for this Information led to a distortion of the potential 
value of tacrollmus. Historical controls from the Pittsburgh experience suggested that tacrollmus was a critical 
Immunosuppressant, and the randomized trial against cyclosporine confirmed the drug's ability to compete. The 
multicenter liver trial, however, was not balanced across treatment arms for other Immunosuppressive agents (Ie, 
higher doses of prednisone from center to center, additional Induction protocols at various centers). Additionally, 
analysis of study results differed across continents, and the role of tacrollmus in cyclosporlne rescue was not 
examined thoroughly. When tacrollmus was proposed for use In extrahepatic organ tranaplantatlon, again the 
Pittsburgh experience, as well as experience from other single centers, was determined Inadequate evidence of 
efficacy, and randomized trials were required by the FDA. The fact that multicenter trials In transplantation have 
historically been poorly deSigned or analyzed weighed against the dramatic Improvements shown from historically 
controlled studies or slngle-center trials should lead to question of the regulatory requirement for multicenter 
randomized trials for all organ types. 
c 1998 by the Nstlonsl Kidney Foundation, Inc. 
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M UCH OF THE discussion at this consen-
sus symposium on immunosuppressive 
drug testing has concerned the clinical andlor 
histopathological diagnosis of rejection. As im-
portant as this may be, it is not the core issue that 
we should be examining. Most errors in the 
evaluation of new immunosuppressants can be 
traced to the design, conduct, and analysis of 
clinical trials. In turn, the scientific consider-
ations that go into what is indisputably a human 
experiment are inseparable from the ethical con-
text into which they are placed. I•3 Questions 
about the probity of trials with experimental 
agents to control rejection were not commonly 
asked until 15 years ago for the simple reason 
that the historical results were so unsatisfactory. 
With the advent of cyclosporine. the permissive 
attitude about deviations from preexisting rou-
tine hardened to reflex skepticism and resistance. 
CYCLOSPORINE BENCHMARK 
When cyclosporine was first used clinically as 
monotherapy or in combination with myelotoxic 
agents:' multiple serious side effects were ob-
served. These were brought into an acceptable 
range by combining cyclosporine with dose-
maneuverable prednisone5 and later with the 
addition of third, fourth, and even fifth agents. 
These were more potent versions of the previous 
best azathioprine/prednisone6 or azathioprine! 
antilymphocyte gloublin (ALG)/prednisone cock-
tails' that had been in common use for almost 
two decades. The cyclosporine-based recipes that 
were developed with kidney transplantation im-
proved the prognosis of all organ recipients and 
elevated liver transplantation overnight to practi-
cal and widespread use.8 
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TACROLIMUS 
Rescue Phenomenon 
Cyclosporine remained the unchallenged base-
line immunosuppressant for all varieties of trans-
plantation until it was shown in 1989 that intrac-
tably rejecting liver allografts could be regularly 
rescued by replacing cyclosporine with tacro-
limus.9 Since this original report, numerous con-
firmatory descriptions have been published. It 
also was promptly recognized that tacrolimus 
could salvage rejecting hearts, kidneys, and other 
organs as well. In virtually all such cases, a 
switch back to cyclosporine was never made. 
Pilot Primary Treatment Experience 
By early 1990, more than 150 liver, kidney, 
heart, -and heart-lung recipients had been treated 
in Pittsburgh with tacrolimus rather than cyclo-
sporine from the time of transplantation.10- 12 It 
had been learned that the three major side effects 
of the drug (nephrotoxicity, neurotoxicity, and 
diabetogenicity) were comparable to cyclospor-
ine. Hypertension and hyperlipidemia were less 
than in historical cyclosporine controls, and the 
cosmetic effects of cyclosporine (hirsutism, gin-
gival hyperplasia, and facial brutalization) had 
not been seen.10-14 Although it was recognized 
that these first patients had been started on too 
much tacrolimus, complications of overdosage 
had been minimized by using the characteristic 
side effects cited above to determine dose ceil-
ings from the first day of treatment onward. 
Rejection established the dose fioor.".l2.IS.16 From 
these observations, the meaning of drug plasma 
level concentrations was quickly deduced. This 
allowed drug trough level monitoring to be ex-
ploited in subsequent cases. This sequence of 
development was no different than that followed 
a decade earlier with cyclosporine.17 
In addition, the availability of an on-site plasma 
assay laboratory in Pittsburgh 18 (the only one 
outside of Japan l9) allowed the pharmacokinet-
ics of tacrolimus in humans to be delineated by 
early 1990. Relative to cyclosporine, the new 
drug's absorption was disturbed very little by the 
absence of bile or by intestinal disorders. How-
ever, its rapid elimination was more dependent 
on good liver function.lS.18.20.21 As a consequence 
of both factors, recipients of poorly functioning 
hepatic grafts had been observed to have plasma 
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trough concentrations nearly 50 times those con-
sidered optimal. 15,21 Even when the hepatic grafts 
functioned well, liver recipients required on aver-
age only slightly more than half the dose of 
kidney recipients to achieve equivalent trough 
plasma levels. II 
MULTICENTER LIVER 
TRANSPLANT TRIALS 
Although all of the foregoing information was 
widely known at the time the multicenter liver 
trials began in late August22 and late September 
1990,23 group decisions were made on both sides 
of the Atlantic to use the high starting doses of 
tacrolimus that already had been abandoned in 
the pilot center. Within a few weeks after the 
trials began, a worldwide epidemic of toxicity 
reports resulted. Formal dose revisions were not 
made until 30% and 18% of the European and 
American tacrolimus case enrollment, respec-
tively, had occurred. The gap between the multi-
center study starting doses and those in concur-
rent use in Pittsburgh never closed, even by the 
end of these trials (Fig 1). 
The multicenter investigators were themselves 
the architects of the treatment protocols after 
consultation with the government regulatory 
agencies and officials of the sponsoring drug 
company (Fujisawa Pharmaceutical Co, Ltd, 
Osaka, Japan). No familiarization (pilot) cases 
were allowed using the drug from the time of 
transplantation. Despite this handicap, the syste-
matic error in dosing, and the disadvantage of not 
having on-site assay for drug monitoring of tacro-
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Fig 1. Starting Intravenous doses used In Pitts-
burgh (solid line) and In the United States and Euro-
pean multicenter trials (dotted line). 
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limus, the investigators who had vast cumulative 
experience with cyclosporine-based immunosup-
pression salvaged the trials. This accomplish-
ment showed how quickly a talented group of 
clinician-investigators in 20 different centers (12 
American, 8 European) could surmount a learn-
ing curve for an experimental drug and introduce 
flexibility into excessively rigid management pro-
tocols that cannot be applied in exactly the same 
way to any two recipients. It also demonstrated 
that the drug was user-friendly. The down side, 
however, was that a distorted picture of the new 
drug's potential value emerged, in contrast to 
that clearly delineated in the earlier Pittsburgh 
experience. 
DEStGN AND OUTCOME OF LIVER 
TRANSPLANTATION TRIALS 
Historically Controlled Pittsburgh Series 
In the 32 years of this program (which had 
begun at the University of Colorado), only two 
major improvements in patient survival have 
occurred from the level established with the 
cocktail of azathioprine, prednisone, and ALG. 8 
The first came in 1980 with the advent of cyclos-
porine,8.24 and the second followed the introduc-
tion of tacrolimus. lI .25 A small increment tempo-
rally associated with the availability of the 
University of Wisconsin preservation solution in 
198726.27 was dependent on the delayed rescue 
with tacrolimus of patients ailing on cyclospo-
rine from the immediately preceding era.25 
Improved survival of grafts was almost of the 
same magnitude as the jump that had followed 
the change from azathioprine to cyclosporine 
(Fig 2).11.25 With primary tacrolimus treatment, 
graft loss from refractory rejection occurred in 
only 1 % to 2% of cases. 11.2S Of the 1,391 liver 
recipients entered. only 35 (2.5%) crossed over 
from tacrolimus to cyclosporine; of these, 15 
changed back when rejection supervened. 
Pittsburgh Randomized Trial 
In this single-center trial.28 tacrolimus and 
cyclosporine were compared head to head. All 
treatment variables other than discretionary use 
of the competing drugs were equal at the outset 
including a daily dose of 20 mg prednisone (Fig 
3). Thus. the occurrence of rejection and the 
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Fig 2. Liver allograft survival during the 3O-year 
history of the program at the Universities of Colorado 
(1963-1980) and Pittsburgh (1981-1993). The eras were 
defined by major Improvements. The dates of case 
accrual from bottom to top curves were 1963-1979 
(group 1), 1980-1987 (group 2), 1987-1989 (group 3), 
and 1989-1993 (group 4). Groups 3 and 4 had signifi-
cantly different survival (P < 0.000). AZA, azathio-
prine; CyA-EC, cycloaporln.Eurocolllns solution. 
need to treat it with additional prednisone or 
other adjuvant therapy directly reflected the effi-
cacy of the competing drugs. Treatment failure 
was precisely defined by the inability to control 
biopsy-confirmed rejection with an orderly se-
quence of escalating secondary intervention. If 
these maneuvers were unsuccessful. switch to 
the other baseline drug was permitted. The side 
effects and other complications were automati-
cally recorded. Crossover in either direction was 
permitted but discouraged. 
The trial (February 1990-November 1991)28 
was characterized by the rapid movement of 
patients off the cyclosporine arm. Eventually, 47 
of the 75 patients randomized to cyclosporine 
switched, triggered by treatment failure under 
steroid-sparing conditions of the protocol. 29 With 
the rescue capabilities of tacrolimus, I-year pa-
tient survival (with intent-to-treat analysis) was 
94% tacrolimus versus 89% cyclosporine with 
I-year graft survival of 90% versus 80% (not 
Ad hoc Dose Adjustments Ad hoc DOS8 Adjustments 
Fig 3. "Balanced" experimental design In Pitts-
burgh randomized trial. 
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significant). At the end of 4 years' follow-up, 
patient survival was 85% in both arms, and graft 
survival was 80% tacrolimus versus 77% cyc1o-
sporine (not significant).29 Because the near par-
ity of results in the two arms was so dependent 
on the rescue qualities of tacrolimus, the use of 
the intent-to-treat analysis has been questioned. 
However, there was a significantly lower inci-
dence of rejection with tacrolimus, a reduced 
need for steroids, and several other quality-of-
life advantages. 
The study was terminated in 1991 at the recom-
mendation of a multi-institutional Patients' Rights 
Committee. A full accounting of the trial is 
provided elsewhere.29 
Multicenter Trials 
In-addition to the excessive tacrolimus dosing 
(see earlier), the unbalanced use of secondary 
immunosuppressants (Fig 4) was scientifically 
controversial. The cyclosporine arm was up-
loaded with twice the induction doses of predni-
sone in all 12 American centers, a third drug 
(azathioprine) in 10 centers, and a fourth agent 
(polyclonal ALG) in one. The eight European 
protocols were similar. On both sides of the 
Atlantic, cyclosporine dose selection for induc-
tion and subsequent adjustment were at the phy-
sicians' discretion. In contrast, the high starting 
doses of tacrolimus were obligatory, and dose 
adjustments were hampered by delay in drug-
monitoring results caused by shipping samples to 
reference laboratories in distant cities. Drug cross-
over in either direction was permitted for intrac-
table rejection but only from tacrolimus to cyclos-
porine for the indication of side effects. 
European. The trial involved 545 patients. A 
5% better patient survival was recorded on the 
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tacrolimus arm (46 v 61 deaths) and a 5% higher 
graft survival,23 The survival advantage was not 
statistically significant, but the authors noted that 
approximately 10% of the surviving grafts cred-
ited to cyc1osporine had been rescued with tacro-
limus. The distorting roles of tacrolimus overdos-
age and a high rate of toxicity were partially 
clarified by separate analyses of the early (high 
dose) and late (reduced dose) phases of the trial. 
The statistical analysis, based on the intent-to-
treat approach, showed significantly greater free-
dom from acute rejection, intractable acute rejec-
tion, and chronic rejection. 
American. Of the 529 enrolled patients, only 
65% completed the first year of this study (180 
tacrolimus, 164 cyclosporine). Although the pub-
lished report was claimed to be by intent-ta-treat 
analysis, the only analyses actually done by 
intent-to-treat were patient survival and graft 
survival, which were not significantly different 
in the two arms.22 The rescue role of tacrolimus 
in reducing the overall incidence of retransplan-
tation was obliquely acknowledged in the discus-
sion: "The low number of second transplanta-
tions for refractory rejection may have been due, 
in part, to the effectiveness of tacrolimus in 
treating patients in the cyc1osporine group who 
had refractory rejection." In fact, grafts rescued 
by tacrolimus accounted for 20 of the 210 surviv-
ing grafts (9.5%) credited by intent-ta-treat analy-
sis to the cyclosporine arm at the end of the year. 
Extensive case censoring, misuse of the 
Kaplan-Meier method, and violations of the in-
tent-to-treat principle led to a reanalysis (which 
has been published elsewhere30) of the original 
database. With reanalysis, freedom from rejec-
tion as a single endpoint, as well as combined 
freedom from all of the secondary endpoints was 
greater. It was noteworthy that drug toxicity had 
an almost immeasurable effect on the tacrolimus 
superiority, correcting the impression left by the 
original reponll that the greater tacrolimus effi-
cacy was balanced out by increased toxicity. 
The most clinically relevant result of the re-
analysis was that after 1 year of follow-up, 98% 
of the tacrolimus-randomized patients had free-
dom from the diagnosis of refractory rejection 
versus only 87% in the competing arm. In addi-
tion. the composite freedom at 1 year from the 
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three factors that haunt transplant recipients (re-
fractory rejection, retransplantation, and death) 
was 80% tacrolimus versus 70% cyclosporine.3o 
KIDNEY AND OTHER ORGAN 
TRANSPLANTATION 
Historically, kidney transplantation was the 
whole-organ procedure with which new immuno-
suppressive drugs and regimens were evalu-
ated.4.6.7.31-33 This precedent was broken with the 
large-scale randomized liver transplant trials. The 
decision to go forward with the multicenter trials 
was made despite prima facie evidence of tacro-
limus superiority from the increasingly well-
documented rescue of liver allografts (see ear-
lier) and shortly thereafter of intractably rejecting 
kidneys34- and hearts.35 Remarkably, this experi-
ence that was promptly confirmed in multiple 
other centers was dismissed as a basis for regula-
tory approval because of the difficulty (and ethi-
cal unacceptability) of obtaining "controls." 
Meanwhile, recipients of extrahepatic organs 
treated with tacrolimus in Pittsburgh (and soon 
elsewhere) from the time of transplantation were 
reported to enjoy the same advantages with this 
drug as the early liver recipients.12.3S.36 A random-
ized renal transplantation trial of tacrolimus ver-
sus cyclosporine was carried out in Pittsburgh in 
1990 and 199}37 but was suspended less than a 
year after its inception at the recommendation of 
the same Patients' Rights Committee that had 
taken similar action with the liver trial (see 
earlier). 
Although the patient and graft survival in the 
single-center randomized kidney transplant trial 
was equal on the two treatment arms, the parity 
by intent-to-treat analysis was dependent on the 
salvage of intractably rejecting crossover pa-
tients rescued with tacrolimus as well as on 
higher average steroid doses in patients kept on 
cyclosporine. The same results were obtained 
later in single-center trials of lungJ8 and heart 
transplantation.J9 Surprisingly, with this wealth 
of information. a second regulatory precedent 
was broken by an FDA decision that randomized 
trials would be mandatory for every kind of 
transplantation. organ by organ, rather than con-
sidering the lessons from the liver and other 
transplant trials to be generic. 
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DISCUSSION AND CONCLUSION 
Disquieting scientific and social issues were 
exposed by the events during the 6 years follow-
ing the placement of tacrolimus on the FDA 
"fast track" in November 1989. The issue of the 
new drug's unusual rescue capability was never 
in doubt, and the question of its superiority as the 
primary baseline agent was scarcely less clear by 
the time the multicenter liver trials were started. 
It is not unreasonable, therefore, to ask why the 
multicenter liver trials were performed and why 
such trials with other organs are still ongoing. 
Although a properly designed and executed 
randomized controlled trial (RCT) is the best 
way to determine the effectiveness of competing 
patient therapies, such studies have been under-
represented in the surgicalliterature.40.41 A par-
tial explanation has been provided by Solomon 
and McLeod42 who found that even in an ideal 
clinical research setting only 40% of questions 
involving a surgical procedure could have been 
answered by a correctly formulated RCT. Al-
though they generally favor such studies when-
ever feasible, the authors stated that ". . . if a 
new treatment is shown to result in a dramatic 
improvement in outcome in uncontrolled, imme-
diate historic controlled trials or non-RCT, a 
ReT may be unnecessary or even unethical. "42 
Was there such an absence of equipoise at the 
time of the multicenter liver trials? Almost cer-
tainly yes. if the observations from Pittsburgh on 
rescue as well as baseline therapy with tacro-
limus were valid. Independent confirmation was 
required at other centers. The ostensible options 
from which the FDA could have selected for this 
purpose are listed in Table 1. However, the 
agency has increasingly insisted on multicenter 
controlled randomized trials as a prerequisite for 
marketing new drugs, and this was the decision 
with tacrolimus. It has been repeatedly stated and 
often persuasively argued that inappropriate 
and/or ineffective therapy can become institution-
alized without such trials on the basis of case 
series and retrospective studies. 
The randomized trial policy has powerful sup-
port in university circles. for reasons that go well 
beyond its intellectual merit. Fiscal. administra-
tive, and professional opportunities are gener-
ated within each component of the "regulatoryl 
pharmaceutical/academic complex" that drives 
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Table 1. Spectrum of Moat to Least 
"Adequate" Controls 
Placebo concurrent control (randomized, double-
blinded) 
Dose-comparison concurrent control (randomized, 2 
doses, often with placebo or active treatment arm 
[established drug)) 
No treatment concurrent control (randomized, with no 
treatment arm) 
Active treatment concurrent control (randomized vcom-
peting agent) 
Historical control vconcurrent treatment (special situa-
tions, when outcome Is self-evident or in absence of 
equipoise) 
Data from Code of Federal Regulations (CFR 314.126). 
Revised by FDA April 1, 1994. 
such trials. The consequent range of possible 
confticts- of interest has made randomized trials a 
magnet for criticism. The most damaging poten-
tial allegation has been that such studies are 
frequently performed to obtain answers that are 
already known 1-3; the multicenter tacrolimusl 
cyclosporine liver and more recent other organ 
trials are prime examples.30 
Reform in the evaluation of immunosuppres-
sive drugs will have to begin with the FDA for 
two reasons. The sole purpose of this agency is 
public service, unlike the other participants in the 
pharmaceutical/academic/regulatory triad. Sec-
ond, the FDA is self-empowered to select the 
requisite evidentiary pathways (meaning what 
controls) that can lead a drug to the market place 
(Table 1). The FDA does not ostensibly engage 
in human experimentation and recoils reftexively 
at the allegation. However, when it determines 
that a multicenter randomized trial, rather than 
one of the other available options (such as histori-
cal controls), is a condition for sale of a new 
drug, the agency becomes the de facto instigator 
of a human experiment and the silent partner of 
the investigating physicians, Institutional Re-
view Boards, and pharmaceutical companies who 
must supervise or perform the study. It is not 
possible to pull this switch and disavow responsi-
bility for what follows. 
Can ill-advised or poorly designed random-
ized trials have an effect opposite to the objec-
tives of improved and less-expensive patient 
care? The answer involves more than the conse-
quent increase in drug cost that eventually is 
passed on to the patients and public. Gjertson. 
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Cecka, and Terasaki43 recently reported evidence 
from 24 American kidney transplant centers with 
access to tacrolimus that the projected actuarial 
half-life of cadaver renal allografts was 14 years 
in recipients treated from the outset with this 
drug versus 8 years using any previously avail-
able immunosuppressant including cyclosporine. 
The investigators concluded: "Based on this 
study, PKS06 (tacrolimus) appears to be the first 
therapeutic agent [in the history of the field] to 
significantly improve long-term kidney graft sur-
vival rates. "43 
H these projections prove to be valid, the 
cumulative unnecessary expenses assumed by 
the taxpayer during the 5-year delay in use of 
tacrolimus for renal transplantation engendered 
by current regulatory policies will have been 
almost beyond imagination. During this period, 
approximately 25,000 primary renal transplanta-
tions were reported to the United Network for 
Organ Sharing Scientific Registry (the data source 
for the study43), almost all under cyclosporine. 
Adding a conservative 5 years' graft function to 
each successful transplantation (at 1 year, tacro-
limus 91 % and cyclosporine 87%) and assuming 
that the cost of returning to dialysis exceeds that 
of late posttransplant care by $10,OOO/yr, the 
potential cost savings that have been lost, even 
taking into account patient mortality, calculates 
well in excess of one billion dollars. 
NOTE ADDED IN PROOF 
March 26, 1998: This article was submitted at 
the time of the consensus development meeting 
on May 13, 1995. Except for completion of 
citations then in press, it has not been changed. It 
is noteworthy that the experience with tacro-
limus accrued since then in many centers has 
been consistent with the earlier views. 
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